D3 Bio
Zhiqiang Chen has a diverse work experience in biologics CMC and protein science. Zhiqiang currently serves as the Executive Director and Head of Biologics CMC at D3 Bio since 2021. Prior to this, they were the Director and Senior Director of CMC and Protein Science at Adagene from 2018 to 2021. During this period, they were responsible for overseeing all CMC activities from preclinical development through clinical supplies for global clinical and registration studies. Zhiqiang also managed CDMOs to ensure timely execution of CMC activities. From 2014 to 2018, they were a Scientist I&II at Bristol-Myers Squibb, where they worked on biologics process development, and published several papers and patents related to protein purification and design of therapeutic IgG4.
Zhiqiang Chen holds a Bachelor of Engineering (BEng) in pharmaceutical engineering from Tianjin University and a Doctor of Philosophy (PhD) in Chemical and Materials Science Engineering from the University of Kentucky.
This person is not in any teams
This person is not in any offices
D3 Bio
1 followers
D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, their new medicine development approach is fundamentally differentiated. They do not just only start with science in the lab. First, they pinpoint the greatest unmet patient and market needs – where existing standard-of-care approaches yield unsatisfactory clinical outcomes. Then they take those insights into lab to guide the identification of fit for purpose science and technology, and define their drug development path. D3 Bio R&D programs are also designed to create a structure, which would enable us to create a robust portfolio and identify assets carrying “back-bone” property for developing future therapies in multiple indications. Their portfolio will include assets from internal effort as well as assets in-licensed in pre-clinical or clinical-stage investigational compounds. This cycle of innovation is at the heart of D3 Bio. In fact, it underlies their name: Development leading to Discovery that then leads back to more Development, or D3 Bio.” D3 Bio is backed by a syndicate of world-class investors whose support underscores their belief in the promise of the Company. Major investors include Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec's Corporate Venture Fund.